Limits...
Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.

Torres M, García-García L, Cruz-Hervert P, Guio H, Carranza C, Ferreyra-Reyes L, Canizales S, Molina S, Ferreira-Guerrero E, Téllez N, Montero-Campos R, Delgado-Sánchez G, Mongua-Rodriguez N, Sifuentes-Osornio J, Ponce-de Leon A, Sada E, Young DB, Wilkinson RJ - Eur. Respir. J. (2014)

Bottom Line: We designed a two-group, two-arm, randomised clinical study of tuberculin skin test-positive participants: 26 with documented contact with TB patients and 34 with non-documented contact.During isoniazid therapy, a significant increase from baseline in the proportion of IFN-γ responders to the 10-kDa culture filtrate protein, Rv2031, Rv0849, Rv1986, Rv2659c, Rv2693c and the recombinant Rv1737 protein was observed (p⩽0.05).The peptide pool of Rv0849 and Rv1737 recombinant proteins induced the highest percentage of IFN-γ responders after isoniazid therapy.

View Article: PubMed Central - PubMed

Affiliation: Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.

No MeSH data available.


Related in: MedlinePlus

Percentage of interferon-γ responders during and after isoniazid treatment. a) Percentage of responders to ESAT-6-1, ESAT-6-2, ESAT-6-1 or ESAT-6-2 (labelled as ESAT-6), CFP-10-1, CFP-10-2, CFP10-1 or CFP10-2 (labelled as CFP-10), and combined ESAT-6 or CFP-10 remained similar during and after treatment. b) Responses to Rv0081, Rv0569 and Rv2031 were lower than responses to antigens shown in panel a. The percentage of responders remained stable or slightly increased during or after treatment. c) Responses to Rv0288c and Rv3019c decreased during or after treatment. d) Responses to antigens Rv0826, Rv0849, Rv1986-1, Rv1986-2, Rv2659c and Rv2693c tended to increase during and after treatment. e) Response to Rv1737, purified protein derivative (PPD) and phytohaemagglutinin (PHA). ESAT-6: 6-kDa early secretory antigenic target; CFP-10: 10-kDa culture filtrate protein.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4318657&req=5

Figure 3: Percentage of interferon-γ responders during and after isoniazid treatment. a) Percentage of responders to ESAT-6-1, ESAT-6-2, ESAT-6-1 or ESAT-6-2 (labelled as ESAT-6), CFP-10-1, CFP-10-2, CFP10-1 or CFP10-2 (labelled as CFP-10), and combined ESAT-6 or CFP-10 remained similar during and after treatment. b) Responses to Rv0081, Rv0569 and Rv2031 were lower than responses to antigens shown in panel a. The percentage of responders remained stable or slightly increased during or after treatment. c) Responses to Rv0288c and Rv3019c decreased during or after treatment. d) Responses to antigens Rv0826, Rv0849, Rv1986-1, Rv1986-2, Rv2659c and Rv2693c tended to increase during and after treatment. e) Response to Rv1737, purified protein derivative (PPD) and phytohaemagglutinin (PHA). ESAT-6: 6-kDa early secretory antigenic target; CFP-10: 10-kDa culture filtrate protein.

Mentions: We assessed the response to two peptide pools of both ESAT-6 and CFP-10, which have been used in IFN-γ release assays during treatment of LTBI [8–10]. Compared with the baseline, multivariate analyses indicated a significant increase in the proportion of responders to CFP-10-1 at week 1 (table 3 and fig. 3a). The increase in response to the rest of the peptides of these proteins and the combined response to ESAT-6 or CFP-10 (table S3 and fig. 3a) were not significant.


Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.

Torres M, García-García L, Cruz-Hervert P, Guio H, Carranza C, Ferreyra-Reyes L, Canizales S, Molina S, Ferreira-Guerrero E, Téllez N, Montero-Campos R, Delgado-Sánchez G, Mongua-Rodriguez N, Sifuentes-Osornio J, Ponce-de Leon A, Sada E, Young DB, Wilkinson RJ - Eur. Respir. J. (2014)

Percentage of interferon-γ responders during and after isoniazid treatment. a) Percentage of responders to ESAT-6-1, ESAT-6-2, ESAT-6-1 or ESAT-6-2 (labelled as ESAT-6), CFP-10-1, CFP-10-2, CFP10-1 or CFP10-2 (labelled as CFP-10), and combined ESAT-6 or CFP-10 remained similar during and after treatment. b) Responses to Rv0081, Rv0569 and Rv2031 were lower than responses to antigens shown in panel a. The percentage of responders remained stable or slightly increased during or after treatment. c) Responses to Rv0288c and Rv3019c decreased during or after treatment. d) Responses to antigens Rv0826, Rv0849, Rv1986-1, Rv1986-2, Rv2659c and Rv2693c tended to increase during and after treatment. e) Response to Rv1737, purified protein derivative (PPD) and phytohaemagglutinin (PHA). ESAT-6: 6-kDa early secretory antigenic target; CFP-10: 10-kDa culture filtrate protein.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4318657&req=5

Figure 3: Percentage of interferon-γ responders during and after isoniazid treatment. a) Percentage of responders to ESAT-6-1, ESAT-6-2, ESAT-6-1 or ESAT-6-2 (labelled as ESAT-6), CFP-10-1, CFP-10-2, CFP10-1 or CFP10-2 (labelled as CFP-10), and combined ESAT-6 or CFP-10 remained similar during and after treatment. b) Responses to Rv0081, Rv0569 and Rv2031 were lower than responses to antigens shown in panel a. The percentage of responders remained stable or slightly increased during or after treatment. c) Responses to Rv0288c and Rv3019c decreased during or after treatment. d) Responses to antigens Rv0826, Rv0849, Rv1986-1, Rv1986-2, Rv2659c and Rv2693c tended to increase during and after treatment. e) Response to Rv1737, purified protein derivative (PPD) and phytohaemagglutinin (PHA). ESAT-6: 6-kDa early secretory antigenic target; CFP-10: 10-kDa culture filtrate protein.
Mentions: We assessed the response to two peptide pools of both ESAT-6 and CFP-10, which have been used in IFN-γ release assays during treatment of LTBI [8–10]. Compared with the baseline, multivariate analyses indicated a significant increase in the proportion of responders to CFP-10-1 at week 1 (table 3 and fig. 3a). The increase in response to the rest of the peptides of these proteins and the combined response to ESAT-6 or CFP-10 (table S3 and fig. 3a) were not significant.

Bottom Line: We designed a two-group, two-arm, randomised clinical study of tuberculin skin test-positive participants: 26 with documented contact with TB patients and 34 with non-documented contact.During isoniazid therapy, a significant increase from baseline in the proportion of IFN-γ responders to the 10-kDa culture filtrate protein, Rv2031, Rv0849, Rv1986, Rv2659c, Rv2693c and the recombinant Rv1737 protein was observed (p⩽0.05).The peptide pool of Rv0849 and Rv1737 recombinant proteins induced the highest percentage of IFN-γ responders after isoniazid therapy.

View Article: PubMed Central - PubMed

Affiliation: Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.

No MeSH data available.


Related in: MedlinePlus